Trading Companies and Distributors

GRAND HOLDING

GRAND HOLDING released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 22.05 B, actual EPS CNY 0.1152

GRAND HOLDING to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

GRAND HOLDING to Release FY2025 Earnings on April 24 After-Market (BJT)

GRAND HOLDING released FY2025 Q4 earnings on April 10 After-Market (BJT), actual revenue CNY 11.57 B, actual EPS CNY -0.3124

GRAND HOLDING released FY2025 earnings on April 10 After-Market (BJT), actual revenue CNY 75.05 B, actual EPS CNY -0.26

GRAND HOLDING released FY2025 9 Months earnings on October 26 After-Market BJT, actual revenue CNY 63.48 B, actual EPS CNY 0.0632

GRAND HOLDING released FY2025 Q3 earnings on October 26 After-Market BJT, actual revenue CNY 21.8 B, actual EPS CNY 0.0061

GRAND HOLDING to Release FY2025 Q3 Earnings on October 27 After-Market BJT

GRAND HOLDING released FY2025 Semi-Annual earnings on August 26 During-Market BJT, actual revenue CNY 41.68 B, actual EPS CNY 0.0571

GRAND HOLDING released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue CNY 22.13 B, actual EPS CNY 0.0316

GRAND HOLDING to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

YUANDA Holdings Expected to Turn Profit in H1 2025

YUANDA Holding's Wholly-Owned Subsidiary YUANDA Qihuang Biotechnology Co., Ltd. Established

Supervisor of YuanDa Holding Increases Shareholding

GRAND HOLDING released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 19.55 B, actual EPS CNY 0.0254

GRAND HOLDING released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 6.681 B, actual EPS CNY -0.4346

GRAND HOLDING released FY2024 Annual Earnings on April 24 After-Market (BJT), Actual Revenue CNY 73.28 B, Actual EPS CNY -0.59

GRAND HOLDING to Release FY2025 Q1 Earnings on April 29 After-Market BJT

GRAND HOLDING to Release FY2024 Annual Earnings on April 25 After-Market BJT

Yuan Da Holdings Receives Warning Letter from Jiangsu Securities Regulatory Bureau Due to Goodwill Impairment Testing Issues

00512

513700

159992

520690

000963

588130

000626

516930

Grand Pharmaceutical Group (SEHK:512) has received China approval for eye treatment GPN01768 and advanced migraine drug GPN01020 to Phase II trials. The stock trades at HK$7.22, with a 6.49% return over the past week but a 7.44% decline over 90 days. The P/E ratio of 20.4x suggests good value compared to its fair P/E of 25.1x and peer average of 21.6x, despite risks from clinical trials and revenue concentration. A DCF model estimates a future cash flow value of HK$22.44 per share, indicating a significant valuation gap.

Simplywall

GRANDPHARMA

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

HUADONG MEDICINE

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI All Share Health Care Devices ETF

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update

CS精准医

Belief BioMed and Grand Life Sciences have announced an exclusive partnership to commercialize BBM-H803, a gene therapy for hemophilia A, in China, Hong Kong, Macau, and Taiwan. This collaboration aims to leverage both companies' strengths to accelerate the commercialization process and improve patient access to innovative treatments. The agreement was signed by key executives from both companies, highlighting their commitment to addressing the unmet clinical needs of hemophilia A patients. BBM-H803 is an AAV-based gene therapy designed to enhance coagulation factor levels in patients, with ongoing trials and regulatory approvals in place.

prnewswire

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

01:48 ETBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

According to the Zhitong Finance APP, GRAND HOLDING released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 63.484 billion yuan, a year-on-year decrease of 4.68%. The net profit attributable to shareholders of the listed company was 32.181 million yuan, a year-on-year increase of 142.30%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 179 million yuan

Zhitong

GRAND HOLDING released its performance for the first three quarters, with a net profit attributable to the parent company of 32.181 million yuan, a year-on-year increase of 142.30%

002084

002513

600748

603933

002208

In the afternoon, high-profile stocks continued to adjust, with SID and Construction Machinery both hitting the limit down. Previously, Huajian Group and RAYNEN also hit the limit down, followed by LFBC, Sanfu Co., Ltd., HUCD, Seagull, GRAND HOLDING, and others

Seagull

LFBC

RAYNEN

HUCD

High-profile popular stocks continue to adjust

GRAND HOLDING experienced significant fluctuations during the trading session, performing a "limit up and limit down," currently reported at 10.74 yuan, with a transaction volume of 615 million yuan

GRAND HOLDING experienced significant fluctuations during the trading session, performing a "sky-high limit up."

GRAND HOLDING hit the daily limit down during trading, performing a "Heaven and Earth Board," currently reported at 8.78 yuan, with a transaction amount of 189 million yuan

GRAND HOLDING announced that it will provide guarantees of no more than 400 million yuan for its 5 subsidiaries to apply for credit from CITIC Bank and Shanghai Pudong Development Bank. This guarantee is within the expected limit and does not require further review. The announcement stated that the total amount of external guarantees provided by the company and its holding subsidiaries has exceeded 100% of the most recent audited net assets, with the guarantee amount reaching 11.65 billion yuan, accounting for 495.80% of the audited net assets for the year 2024. The board of directors believes that this guarantee can support the subsidiaries' business and that the risks are controllable

GRAND HOLDING provides a credit guarantee of 400 million for its subsidiary, with the total guarantee amount accounting for nearly 5 times its net assets

According to the Zhitong Finance APP, GRAND HOLDING announced that Mr. Xu Qiang, the vice chairman and vice president who holds 0.6594% of the shares, plans to reduce his holdings by 800,000 shares (accounting for 0.1579% of the company's total share capital) through centralized bidding within three months after the announcement of the reduction plan, starting from 15 trading days thereafter

GRAND HOLDING Vice President Xu Qiang plans to reduce holdings of no more than 800,000 shares

GRAND HOLDING announced that the company completed the repurchase and cancellation of shares on July 31, 2025, with the number of shares canceled accounting for 0.45% of the total share capital before cancellation. The total share capital of the company before cancellation was 509 million shares, which changed to 507 million shares after cancellation. The company plans to use the 2.3136 million repurchased shares for an employee stock ownership plan or equity incentive, but there are currently no implementation plans. This cancellation of shares will not have a substantial impact on the company's financial condition and operating results

GRAND HOLDING: Cancelled 2.3136 million repurchased shares

GRAND HOLDING(000626.SZ)